FSHR agonists(Follicle-stimulating hormone receptor agonists), LHCGR agonists(Luteinizing hormone/Choriogonadotropin receptor agonists), Ovarian follicle stimulants

Therapeutic Areas

Endocrinology and Metabolic DiseaseUrogenital Diseases

Active Indication

Primary Ovarian InsufficiencyAnovulationInfertility, Female+ [1]

Inactive Indication-

Originator Organization

Ferring BV

Active Organization

Huiling Pharmaceutical Consulting (Shanghai) Co., Ltd.Ferring Pharmaceuticals, Inc.

Ferring Pharmaceuticals A/S

+ [1]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (27 Aug 1999),

Infertility, Female

Regulation-

Gene Sequence

Sequence Code 3246α

Sequence Code 3253β

Sequence Code 83626β

Clinical Trials associated with Menotropins

NCT05567731 / CompletedNot ApplicableIIT

Effect of Long, Short, and Ultrashort GnRH Agonist Treatment Protocols in Intracytoplasmic Sperm Injection Candidates on Ovarian Reserve

This study aimed to compare the gonadotropin-releasing hormone agonist (ultra-short) protocol versus (short and long) protocols on ovarian reserve in women undergoing intracytoplasmic sperm injection

Start Date15 Oct 2022

Sponsor / Collaborator

Tanta University

NCT04814940 / WithdrawnNot Applicable

Retrospective Analysis of Real-world Data From Medical Records on the Use of Gonadotropin for Infertility Treatment to Describe the Treatment Patterns and to Understand the Clinical Impact

The purpose of this retrospective observational study is to describe the treatment patterns with MENOPUR and to understand the clinical impact for patients that underwent infertility treatment under real-world setting.
The primary objective is to describe the treatment patterns for the general population and for selected patient profiles.

Start Date01 Sep 2022

Sponsor / Collaborator

Ferring Pharmaceuticals A/S

NCT05103228 / Unknown statusNot ApplicableIIT

Cumulative Pregnancy Rate With Lower and Higher Dose of Gonadotropin During Controlled Ovarian Hyperstimulation During IVF Among Expected Poor Responders: a Prospective, Randomized Controlled Trial

Controlled ovarian hyperstimulation (COH) is an important step during in vitro fertilization (IVF). Its aim optimally is to recruit 10-15 oocytes. When deciding on the actual treatment, different stimulation protocols, various stimulating agents and wide range of gonadotropin dose can one choose from. Prior to the decision on the actual stimulation protocol and gonadotropin (Gn) dose the patient's expected response to stimulation is assessed primarily using ovarian reserve markers. Most medications used during stimulation exert their effect in a dose-dependent manner hence with a higher Gn dose one would expect a better response, more oocytes. More oocytes could translate into more embryos and potentially a higher pregnancy rate. The currently available evidence however does not support this practice as randomized controlled trials (RCT) have failed to show that the use of higher Gn dose results in higher pregnancy, live-birth rates. These studies however identified patients based on different criteria, compared different stimulation protocols and various Gn doses. There are only two RCTs that compared cumulative live birth rates (fresh + frozen embryo transfers) and they identified poor responders based on different criteria and used different drug regimens. Therefore, the aim of our study is to compare cumulative IVF clinical pregnancy rates using a lower and a higher gonadotropin dose among poor responders identified based on universally accepted criteria.

Start Date02 Dec 2021

Sponsor / Collaborator-

100 Clinical Results associated with Menotropins

100 Translational Medicine associated with Menotropins

100 Patents (Medical) associated with Menotropins

2,099

Literatures (Medical) associated with Menotropins

01 Feb 2024·Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Pulsatile Gonadotropin-Releasing Hormone Therapy Is Associated With Better Spermatogenic Outcomes than Gonadotropin Therapy in Patients With Pituitary Stalk Interruption Syndrome

Article

Author: Liu, Hongying ; Zhang, Rui ; Nie, Min ; Zhang, Wei ; Mao, Jiangfeng ; Sun, Bang ; Zhu, Yiyi ; Wu, Xueyan ; Zhang, Junyi ; Wang, Xi

OBJECTIVE:

To compare the effects of combined gonadotropin and pulsatile gonadotropin-releasing hormone (GnRH) therapy on spermatogenesis in patients with pituitary stalk interruption syndrome (PSIS).

METHODS:

Male patients with PSIS (N = 119) were retrospectively studied. Patients received pulsatile GnRH therapy (N = 59) were divided into response and poor-response groups based on luteinizing hormone (LH) levels after 1-month treatment with a cutoff value of 1 or 2 IU/L. Participants with gonadotropin therapy were divided into human menopausal gonadotropin (hMG)/human chorionic gonadotropin (hCG) group (N = 60), and patients with pulsatile GnRH therapy were classified into GnRH group (N = 28) with treatment duration ≥6 months.

RESULTS:

The overall success rates of spermatogenesis for hMG/hCG and GnRH therapy were 51.67% (31/60) vs 33.90% (20/59), respectively. GnRH group required a shorter period to induce spermatogenesis (8 vs 15 months, P = .019). hMG/hCG group had higher median total testosterone than GnRH group [2.16, interquartile range(IQR) 1.06-4.89 vs 1.31, IQR 0.21-2.26 ng/mL, P = .004]. GnRH therapy had a beneficial effect on spermatogenesis compared to hMG/hCG therapy (hazard ratio 1.97, 95% confidence interval 1.08-3.57, P = .026). In patients with pulsatile GnRH therapy, compared with the poor-response group, the response group had a higher successful spermatogenesis rate (5.00% vs 48.72%, P = .002) and higher median basal total testosterone (0.00, IQR 0.00-0.03 vs 0.04, IQR 0.00-0.16 ng/mL, P = .026) with LH = 1 IU/L as the cutoff value after 1-month pulsatile GnRH therapy.

CONCLUSIONS:

Pulsatile GnRH therapy was superior to hMG/hCG therapy for spermatogenesis in patients with PSIS. Earlier spermatogenesis and higher concentrations of sperm could be obtained in the GnRH group if patients received therapy over 6 months.

01 Feb 2024·European journal of radiology

To assess the quantitative features of focal liver lesions in gadoxetic acid enhanced MRI and to determine whether these features can accurately differentiate benign form malignant lesions

Article

Author: Markiet, Karolina E ; Rybczynska, Dorota N ; Szurowska, Edyta ; Frydrychowski, Andrzej ; Pienkowska, Joanna M

PURPOSE:

The study aims at assessing the quantitative features which distinguish focal liver lesions (FLLs) in gadoxetic acid (GA) enhanced liver MRI and at determining whether these features can accurately differentiate benign from malignant lesions.

MATERIAL AND METHODS:

107 patients with 180 unequivocal FLLs in previous examinations were included in a single-center retrospective study. All patients underwent a MRI test of the liver with GA. 99 benign and 74 malignant lesions were included. The group of benign lesions consisted of 60 focal nodular hyperplasias (FNH), 22 hemangiomas (HMG), 6 hepatic adenomas (HA), and 11 other benign lesions (1 angiomyolipioma, 6 lesions histopathology diagnoses as benign without further specification, or ones lacking features of malignancy, and 4 lesions radiologically diagnosed as benign which remained stable in the follow-up studies). The group of malignant lesions consisted of primary 51 hepatocellular carcinomas, 12 metastases, and 11 metastases from melanoma malignum (MM meta). 7 FLLs were excluded (4 cases of uncertain histopathological diagnosis, 2 cholangiocarcinomas, and 1 regenerative nodule). For the included lesions ROI (region of interest) measurements were taken by two observers in the T2-w, ADC (apparent diffusion coefficient) and in the T1-w sequence in the hepatobiliary phase (HBP). The interobserver agreement was evaluated with the Wilcoxon test. The Kruskal - Wallis, Mann - Whitney U and post hoc Dunn's tests were applied to assess if there were any significant differences in the ROI values between individual lesions. The variables with the p values of < 0.05 were considered statistically significant.

RESULTS:

We found significant differences in the ROI values between lesions with p < 0.0001. Strikingly high ROI values in the T2-w sequence were found for HMG. The lowest ADC values were encountered for metastases and MM metastases. The highest ROI values in the HBP were found for FNH, and the lowest for metastases. We also found statistically significant differences in the ROI values between benign and malignant lesions with benign lesions presenting statistically higher ROI values compared to malignant lesions.

CONCLUSIONS:

There were significant differences in the ROI values among different types of FLLs. The predominant quantitative feature in the T2-w sequence was a strikingly high ROI value for HMG. Benign lesions presented statistically higher ROI values in the T2-w, ADC, and HBP sequences compared to malignant lesions. This was true for all lesions except for HA.

05 Jan 2024·Human reproduction open

The cumulative live birth rates of 18 593 women with progestin-primed ovarian stimulation-related protocols and frozen-thawed transfer cycles

Article

Author: Nie, Yunhan ; Shen, Xi ; Guo, Wenya ; Zeng, Yuqi ; Xie, Yating ; Wang, Li ; Gao, Hongyuan ; Liu, Yali

Abstract:

STUDY QUESTION:

What are the odds of achieving pregnancy when adopting progestin-primed ovarian stimulation (PPOS)-related protocols combined with repetitive frozen-thawed transfer (FET) cycles in patients with different clinical characteristics?

SUMMARY ANSWER:

The cumulative live birth rates (CLBRs) of women undergoing different PPOS-related protocols can be significantly and consistently enhanced within six FET cycles when the female age is <40 years (or even <45 years) and when >5 oocytes are retrieved, regardless of antral follicle count (AFC).

WHAT IS KNOWN ALREADY:

There have been numerous studies on the live birth rate of the first FET cycle in patients with PPOS-related protocols. These studies have focused mainly on comparing pregnancy outcomes with those of other stimulation protocols. However, owing to the unique features of the PPOS-related strategy, such as its flexible timing of oocyte retrieval and repeated transfer of frozen embryos, studies using the CLBR as an overall indicator of success and investigating which types of patients would benefit from this protocol are lacking.

STUDY DESIGN, SIZE, DURATION:

This retrospective cohort study included 18 593 women who underwent PPOS-related protocols (dydrogesterone + hMG, medroxyprogesterone acetate + hMG, micronized progesterone + hMG treatment, and luteal-phase ovarian stimulation protocol) from 1 March 2011 to 31 September 2022 in our centre.

PARTICIPANTS/MATERIALS, SETTING, METHODS:

The population was categorized by female age, number of oocytes retrieved, and AFC in the analysis of CLBR within six FET cycles. The age groups (Groups 1–5, respectively) were <30, 30–34, 35–39, 40–44, and ≥45 years. The number of oocytes retrieved was grouped as 1–5, 6–10, 11–15, 16–20, and >20. AFC was grouped as <5, 5–10, 11–15, and >15. The Kaplan–Meier analysis (optimistic method), which hypothesized that patients who did not continue treatment had the same chance of achieving a live birth as those who continued, and the competing risk method (conservative method) which hypothesized they had no chance of achieving a live birth, were applied. In further analyses, the Cox model and Fine–Gray model were adopted: the former corresponds to the optimistic scenario, and the latter corresponds to the pessimistic scenario.

MAIN RESULTS AND THE ROLE OF CHANCE:

CLBR had a declining trend with female age over six FET cycles (Groups 1–5, respectively: optimistic: 96.9%, 96.6%, 91.4%, 67.3%, and 11.7%; conservative: 87.3%, 85.0%, 74.0%, 41.3%, and 7.5%), requiring more FET cycles to achieve a success rate of at least 50% (Groups 1–5, respectively: optimistic: 2, 2, 2, 4, and >6 cycles; conservative: 2, 2, 2, >,6 and >6 cycles). CLBR showed an increasing trend with the number of oocytes retrieved (Groups 1–5, respectively: optimistic: 93.8%, 94.3%, 95.8%, 96.0%, and 95.6%; conservative: 66.2%, 78.3%, 85.6%, 88.9%, and 91.0%). All groups needed the same number of FET cycles to achieve a success rate of at least 50% (Groups 1–5, respectively: optimistic: 2, 2, 2, 2, and 2 cycles; conservative: 2, 2, 2, 2, and 2 cycles). Furthermore, the CLBR within six FET cycles had an increasing trend with AFC number (Groups 1–4, respectively: optimistic: 89.2%, 94.8%, 95.9%, and 96.3%; conservative: 67.4%, 78.2%, 83.9%, and 88.1%), with all four groups achieving a success rate of at least 50% by the second FET cycle.

LIMITATIONS, REASONS FOR CAUTION:

The current research is limited by its retrospective design and single-centre nature, which may restrict the generalizability of our findings.

WIDER IMPLICATIONS OF THE FINDINGS:

This work describes two models (the Kaplan–Meier analysis and the competing risk method) to evaluate the clinical outcome of patients using PPOS-related protocols, which are especially useful for patients of advanced age or those with diminished ovarian reserve. Our findings encourage patients below 45 years old, especially younger than 40 years, and patients with lower AFCs and fewer retrieved oocytes to try this new protocol. Moreover, this study demonstrates the degree of improvement in the CLBR within six FET cycles for patients with different clinical characteristics, providing a valuable point of reference to determine whether to continue ART after a transfer failure.

STUDY FUNDING/COMPETING INTEREST(S):

The study was supported by grants from the National Natural Science Foundation of China (82071603 to L.W., 82001502 to Y.L.). There are no conflicts of interest to declare.

TRIAL REGISTRATION NUMBER:

N/A.

News (Medical) associated with Menotropins

11 Apr 2023

·www.fiercebiotech.com

Ferring's research site closure signals shift from internal to external R&D, CSO says

Ferring Pharma's CSO says the company's commitment to reproductive and maternal health products is unchanged even as R&D priorities shift. After more than 25 years, Ferring Pharmaceuticals suddenly shuttered a San Diego research institute in March just months after finishing a major renovation. It's all part of the plan, says Chief Scientific Officer Armin Metzger, Ph.D. The research executive, now in his seventh year with Ferring, said that the company is making a concerted pivot toward external innovation to make the best use of capital following two FDA approvals at the end of 2022. It's a shift that Metzger describes as a "fundamental" change. "We will still have internal discovery, but [be] much, much more external focused, giving more flexibility of allocating funds," he said in an interview with Fierce Biotech. The clear-eyed assessment of the company’s priorities set the record straight as to why the Ferring Research Institute, one of the company’s three main R&D hubs, closed after 27 years. The move resulted in nearly 90 staffers being laid off and came after Ferring finished renovations on the institute just last year. “[T]he turning point was that we got two FDA approvals of two first-in-class assets in one year,” said Metzger. “And this leads to the adaptation, again of the strategy—how we deliver innovation to the patients—and it is not an easy decision-making process.” In November 2022, Ferring nabbed FDA approval for the first fecal microbiota product, Rebyota, for adults with C. difficile following antibiotic treatment or recurrent infection. Just a few weeks later, gene therapy Adstiladrin was approved for bladder cancer. The new strategy is not a complete departure from Ferring’s existing work, as those now-approved assets originated from deals. Ferring acquired Rebiotix in April 2018, tacking on the C. difficile treatments, and then a month later, the Swiss pharma signed a commercialization agreement with FKD Therapies for the bladder cancer treatment. “I think a company of our size, with the investment needed now on the later stage, we can't entertain technology platforms in-house,” said Metzger, who added that Ferring will instead rely on "partnerships across the globe.” Ferring’s main therapeutic areas are remaining unchanged, however, including maternal and reproductive health, which Metzger called “the core” of the company. One of the priorities is bringing the infertility treatment Rekovelle to the U.S. after it nabbed approval in Europe and Switzerland. He expects feedback from the FDA in the second half of the year. In addition to Rekovelle, infertility treatments LutrePulse and Menopur are under development, along with Pabal, a med for postpartum hemorrhage. But the clinical-stage work is in limbo. A phase 2 trial for a treatment to address inadequate milk production, merotocin, was shuttered earlier this year due to low enrollment and a phase 2 infertility treatment is now absent from the company’s pipeline. A spokesperson for Ferring did not immediately respond to a request for comment on the missing program. Regardless, Metzger says that in the next year, the company hopes to bolster its portfolio, including potentially boosting the indications for merotocin. This could also mean combination opportunities and female and male infertility assets from Ferring's reproductive medicine pipeline.

Drug ApprovalPhase 2AcquisitionGene TherapyLicense out/in

09 Mar 2023

·www.businesswire.com

Approval of New Medicines in 2022 Sets Ferring on Course for Future Growth and Diversification

SAINT-PREX, Switzerland--( BUSINESS WIRE )--Ferring has today published its 2022 Annual Report. The company reported revenues of €2.3 billion, an increase of +5% on the previous year at actual exchange rates, but a slight decrease of -1% at constant exchange rates. The main highlights of the year were the approvals by the US Food and Drug Administration (FDA) for two pioneering new medicines, Rebyota™ (fecal microbiota, live – jslm), a new microbiome treatment, and Adstiladrin ® (nadofaragene firadenovec-vncg), a novel gene-based therapy for bladder cancer. These were approved in November and December 2022 respectively. This means Ferring was responsible for two out of the eight biological medicine products approved by the US FDA’s Center for Biologics Evaluation and Research in 2022. 1 The ground-breaking approvals of Rebyota™ and Adstiladrin ® will provide new options for patients and important mid- to long-term growth and diversification opportunities for Ferring, reflecting our strategy to progress late-stage opportunities and demonstrating our ongoing commitment to scientific innovation. We also continue to demonstrate leadership in reproductive medicine and maternal health. Carbetocin Ferring (carbetocin, room temperature-stable formulation) became our first-ever product to gain prequalification status from the World Health Organization. This will make it easier for more women in low- and lower middle-income countries to access treatment for the prevention of PPH. For the year, revenues showed a slight decrease of -1% at constant exchange rates, after a strong first three quarters of the year. However, in the fourth quarter, Ferring faced challenges when we were made aware of changes in the manufacturing process of the drug substance for Menopur ® (menotropins for injection), one of our leading products used for ovarian stimulation in women undergoing assisted reproductive technologies. Whilst Ferring’s data reviewed to date indicates that the safety and efficacy of the product remain unaltered, this has resulted in supply constraints as we work with health authorities to resolve the situation. Thus, for the year, the reproductive medicine and maternal health portfolio decreased by -2% at constant exchange rates but was largely offset by the solid growth in the rest of the portfolio. The appreciation of several currencies against the euro resulted in revenues achieving growth of +5% at actual exchange rates. In 2022, expenditure increased as business activity returned to normal following the COVID-19 pandemic. We also invested in the field of microbiome in anticipation of the Rebyota™ launch, alongside increased research and development costs as the pipeline evolved and clinical studies were conducted. Despite inflation, we were able to partly mitigate the increase in operating expenses through disciplined cost management. Nevertheless, operating profit decreased to reach €231 million for the year. “ In 2022, we continued to demonstrate the qualities that make Ferring such an enduring force in the world of healthcare: the inspiration and passion to develop pioneering medicines, a consistent focus on the unmet needs of patients, and the resilience to overcome challenges as they arise,” said Per Falk, President of Ferring Pharmaceuticals. “ Our newly approved products provide important avenues for exploration and growth, built upon our established strength in reproductive medicine and maternal health, where we have a long-standing reputation for innovation and remain committed to building families of every shape and size.” About Ferring Pharmaceuticals Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring employs over 7,000 people worldwide. The company has operating subsidiaries in more than 50 countries and markets its products in over 100 countries. Learn more at www.ferring.com , or connect with us on Twitter , Facebook , Instagram , LinkedIn and YouTube . References: 1 U.S. Food and Drug Administration. 2022 Biological License Application Approvals. Available at https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/2022-biological-license-application-approvals . Last accessed 24 February 2023. 2 Trends in Maternal Mortality 2000 to 2017: Estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division. World Health Organization 2019. Available at: https://www.unfpa.org/sites/default/files/pub-pdf/Maternal_mortality_report.pdf Last accessed 24 February 2023. # # #

Drug ApprovalFinancial Statement

100 Deals associated with Menotropins

External Link

KEGG	Wiki	ATC	Drug Bank
D02692	-	G03GA02	DB00032

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Primary Ovarian Insufficiency	US	Ferring Pharmaceuticals, Inc.	19 Feb 2014
Anovulation	US	Ferring Pharmaceuticals, Inc.	29 Oct 2004
Infertility, Female	US	Ferring Pharmaceuticals, Inc.	27 Aug 1999

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Infertility	Phase 3	BE	Ferring Pharmaceuticals A/S	01 Jul 2009
Infertility	Phase 3	CZ	Ferring Pharmaceuticals A/S	01 Jul 2009
Infertility	Phase 3	DK	Ferring Pharmaceuticals A/S	01 Jul 2009
Infertility	Phase 3	PL	Ferring Pharmaceuticals A/S	01 Jul 2009
Infertility	Phase 3	ES	Ferring Pharmaceuticals A/S	01 Jul 2009
Infertility	Phase 3	SE	Ferring Pharmaceuticals A/S	01 Jul 2009
Infertility	Phase 3	TR	Ferring Pharmaceuticals A/S	01 Jul 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02554279 (MEGASET HR, Pubmed \| Fertil Steril) Manual	Phase 4	Ovarian Stimulations	619	highly purified human menotropin	vobjtwinxs(aujqrefmuo) = excuoajreq uxbgzxhkba (hezhtafgcq ) View more	Negative	01 Aug 2020
				recombinant follicle-stimulating hormone	vobjtwinxs(aujqrefmuo) = lufbjpykej uxbgzxhkba (hezhtafgcq ) View more
NCT02738580 (CTgov)	Phase 4	Infertility \| Ovarian Hyperstimulation Syndrome	112	rFSH (rFSH)	xdtczteiwt(krxnmysjcl) = twjthptfwd ewbqaptpcw (zmpidmafsv, zcpddwjgye - uxedqcdlxj) View more	-	03 Mar 2020
				HP-HMG+GnRH antagonists (HP-HMG)	xdtczteiwt(krxnmysjcl) = qclznjmtre ewbqaptpcw (zmpidmafsv, umbcslorln - knktjujsxh) View more
NCT01921166 (Diminished Ovarian Reserve, CTgov)	Phase 4	Infertility	23	Menopur+Clomid+Bravelle+Follistim+Gonal f (Clomiphene Plus Gonadotropins)	cahbizaxff(wfbcfnbicg) = ouserqjrvu uihtcxgotx (wmdnrdltbn, jfcyeammxd - otryuxecqn) View more	-	23 Feb 2018
				Leuprolide flare (Leuprolide Flare)	cahbizaxff(wfbcfnbicg) = bglajckclt uihtcxgotx (wmdnrdltbn, brdvipjris - fzwhyofdxr) View more
NCT02542280 (CTgov)	Phase 3	Infertility \| Endometritis	360	endometrial injury. (Endometrial Injury)	veovvyhutl(pxrkooekyw) = ilicidzhxw apwzqclyfm (ovvqnrqgjp, tzfrfnfnqb - lhgxrdpciy) View more	-	08 Jan 2016
				ovarian stimulation (no Endometrial Injury)	veovvyhutl(pxrkooekyw) = gsaduhsjmy apwzqclyfm (ovvqnrqgjp, gbxividynu - ypizvqotld) View more
NCT01312766 (CTgov)	Phase 3	Infertility	270	Menotropins (hMG-IBSA)	maoeizqynu(rilcrbxcpd) = ndembdsgfv pnzcjxtogu (jpcbuvawex, nioszjtjhc - mkntlobals) View more	-	15 Aug 2014
				Menotropins (Menopur)	maoeizqynu(rilcrbxcpd) = trthzhhqra pnzcjxtogu (jpcbuvawex, iorfiysnqz - bprqhjuwok) View more
NCT01417195 (CTgov)	Phase 4	Infertility	122	Menopur+Bravelle (Menopur and Bravelle Combination)	krvmbfszfw(iuktjgoquj) = pyqcgjkvkz fomufwjcpr (agutsxizah, nndereobnd - izbpnfkwso) View more	-	24 Apr 2014
				Menopur (Menopur Alone)	krvmbfszfw(iuktjgoquj) = tcjbupddua fomufwjcpr (agutsxizah, xnyaifmxzj - kxztotnqfe) View more
NCT01225835 (PREDICT, CTgov)	Phase 4	Infertility	124	Menotrophin+Choriongonadotropin+Cetrorelix+Progesterone (Menotrophin)	hntsoqnvzm(ncoqsqmbad) = bffmrsqqvu hofkiwwwri (fwvhdrajbx, jnvomvvizk - fpxcbpopbw) View more	-	11 Feb 2014
				Choriongonadotropin+Cetrorelix+Progesterone+Follitrophin alpha (Follitrophin Alpha)	hntsoqnvzm(ncoqsqmbad) = ueedxtsioo hofkiwwwri (fwvhdrajbx, ldnoqdrqly - izidbihyvu) View more
NCT00884221 (CTgov)	Phase 3	Infertility	749	Highly purified menotrophin (Highly Purified Menotrophin)	oafbrubwre(evjscwpiou) = tjmytxbevt gjeixmiviv (droqfhtpko, fthmicdeyd - btjlvmpzkh) View more	-	18 Apr 2012
				Recombinant FSH (Recombinant FSH)	oafbrubwre(evjscwpiou) = icxomrmoqs gjeixmiviv (droqfhtpko, nmqhhjfvtb - zyeftpfjmd) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis